As previously stated, two recently approved drugs, tirzepatide, a dual analogue of GIP/GLP-1, and semaglutide, a GLP-1 analogue, were added to the therapeutic arsenal of NAFLD [150]. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.